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Image-based computational 
quantification and visualization 
of genetic alterations and tumour 
heterogeneity
Qing Zhong1,*, Jan H. Rüschoff1,*, Tiannan Guo2, Maria Gabrani3, Peter J. Schüffler4, 
Markus Rechsteiner1, Yansheng Liu2, Thomas J. Fuchs5, Niels J. Rupp1, Christian Fankhauser1, 
Joachim M. Buhmann2, Sven Perner6, Cédric Poyet7, Miriam Blattner8, Davide Soldini1, 
Holger Moch1, Mark A. Rubin8, Aurelia Noske1, Josef Rüschoff9, Michael C. Haffner10, 
Wolfram Jochum11 & Peter J. Wild1
Recent large-scale genome analyses of human tissue samples have uncovered a high degree of 
genetic alterations and tumour heterogeneity in most tumour entities, independent of morphological 
phenotypes and histopathological characteristics. Assessment of genetic copy-number variation 
(CNV) and tumour heterogeneity by fluorescence in situ hybridization (ISH) provides additional tissue 
morphology at single-cell resolution, but it is labour intensive with limited throughput and high inter-
observer variability. We present an integrative method combining bright-field dual-colour chromogenic 
and silver ISH assays with an image-based computational workflow (ISHProfiler), for accurate 
detection of molecular signals, high-throughput evaluation of CNV, expressive visualization of multi-
level heterogeneity (cellular, inter- and intra-tumour heterogeneity), and objective quantification of 
heterogeneous genetic deletions (PTEN) and amplifications (19q12, HER2) in diverse human tumours 
(prostate, endometrial, ovarian and gastric), using various tissue sizes and different scanners, with 
unprecedented throughput and reproducibility.
Next-generation sequencing (NGS) studies of various tumours have uncovered multiple genetic abnormalities 
and extensive tumour heterogeneity, demonstrating its substantial impact on cancer treatment and personalized 
medicine1–4. Yet, NGS studies often preclude potential integrative analysis with the corresponding morphological 
phenotype, thus losing important topological information of tissue architecture. Moreover, genome sequencing 
has usually been performed on bulk tumour specimens, which often fails to identify minor sub-clones and pre-
dict whether the mutations occur in the same or in different cells. Although modern technologies have solved 
these problems by sequencing single cancer cells, their implementations are still inapplicable for large research 
cohorts5.
Fluorescence in situ hybridization (FISH) is a well-established method to measure genetic variations along 
with tissue morphology at cellular resolution6. Nevertheless, the requirement of fluorescence microscopy, fading 
fluorescent signals, and the subjective interpretation of copy number variation (CNV)7–9, impede throughput, 
1Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland. 2Institute of Molecular Systems 
Biology, ETH, Zurich, Switzerland. 3Zurich Labouratory, IBM Research-Zurich, Rueschlikon, Switzerland. 
4Department of Computer Science, ETH, Zurich, Switzerland. 5Memorial Sloan Kettering Cancer Center, New York, 
NY, USA. 6Department of Prostate Cancer Research, Institute of Pathology, University Hospital of Bonn, Bonn, 
Germany. 7Department of Urology, University Hospital Zurich, Zurich, Switzerland. 8Institute for Precision Medicine 
and Department of Pathology and Laboratory Medicine, Weill Medical College of Cornell University and New York-
Presbyterian Hospital, New York, NY, USA. 9Targos Molecular Pathology, Pathology Nordhessen, Kassel, Germany. 
10Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USA. 11Institute of 
Pathology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland. *These authors contributed equally to this work. 
Correspondence and requests for materials should be addressed to P.J.W. (email: peter.wild@usz.ch)
Received: 08 February 2016
Accepted: 22 March 2016
Published: 07 April 2016
OPEN
www.nature.com/scientificreports/
2Scientific RepoRts | 6:24146 | DOI: 10.1038/srep24146
induce biased assessment among different investigators10–12, and hinder a systematic quantification of tumour 
heterogeneity.
To overcome these limitations, we established a dual-colour chromogenic and silver in situ hybridization 
(DISH) assay to permit bright-field evaluation of morphological details, developed an image-based computational 
workflow (ISHProfiler) to detect CNV at single-cell level, and proposed a statistical analysis to quantify tumour 
heterogeneity for a variety of genes across several cancer entities on tissue microarrays (TMAs) and whole-slide 
images with accompanying visualization tools. Here, we demonstrate the versatility of ISHProfiler and provide 
proof-of-principle evidence for its application to precision medicine for objective patient stratification.
Results
Reference data and a novel scoring method. As reference data for introducing a novel scoring method 
to estimate genetic alterations, we used a TMA of human prostate cancer (PC) hybridized with FISH probes for 
the tumour suppressor gene phosphatase and tensin homolog (PTEN) and the corresponding centromeric probe 
(CEP) of chromosome 10. In contrast to the conventional scoring approach based on estimation of the percentage 
of aberrant nuclei9,12, the new score represents the ratio of PTEN to CEP10 of a given tumour region without the 
requirement for recognizing distinct nuclei13,14, therefore diminishing the signal loss effect caused by cutting arti-
facts15. To benchmark this ratio score for the estimation of PTEN deletion in PC, we used 424 benign and malig-
nant prostate formalin-fixed paraffin-embedded (FFPE) tissue samples, consisting of 339 radical prostatectomy 
(RPE) specimens, 28 castration resistant prostate cancers (CRPCs), 17 lymph node metastases, 11 distant metas-
tases, and 29 benign prostatic hyperplasias (BPHs). PTEN homozygous and hemizygous deletion, based on the 
manual counting of FISH signals and classification at the threshold of 60%9 for both scoring methods, indicated 
significant associations (P < 0.001) of PTEN deletion with different tissue types (Fig. 1a,b). Equivalence of both 
scores was further confirmed by multiple comparisons with clinico-pathologic, immunologic, and genetic features 
of patients receiving RPE (Supplementary Fig. S1 and Supplementary Table S1), by linear correlation (r = − 0.9492, 
P < 0.001; Fig. 1c), and by analysis of overall (log-rank P = 0.017 and 0.003), disease-specific (log-rank P = 0.009 
and 0.005), as well as recurrence-free (log-rank P = 0.209 and 0.387) survival (Supplementary Fig. S2). 
Last, univariate and multivariate Cox regression revealed that PTEN deletion estimated by the ratio score is a 
strong prognostic factor for overall survival in PC (P = 0.0208, hazard ratio = 2.0, 95% confidence interval (CI) 
[1.11–3.60]); Supplementary Fig. S3).
PTEN DISH assay versus FISH assay. We established a PTEN DISH assay to streamline the detection 
of PTEN deletion in a representative subset of 71 tissue samples, providing permanent staining and detailed 
histological morphology compared with FISH (Supplementary Fig. S4). These tissue cores were analysed by both 
PTEN DISH and FISH assays using the ratio score: 38 primary acinar adenocarcinomas from RPE specimens, 
ten CRPCs, six PC lymph node metastases, one distant metastasis, and 16 BPHs. DISH assessment by manual 
counting and ratio scoring of PTEN and CEP10 signals was highly concordant with that of FISH (classifica-
tion accuracy 94.4%, sensitivity 92.3%, and specificity 94.8%; Supplementary Table S2). The sole false negative 
case (FISH: deletion, DISH: no deletion; Fig. 1d, and the zoomed version: Fig. 1e) and three false positive cases 
(Supplementary Fig. S5) strongly supported the notion that misclassifications were attributed to cellular hetero-
geneity (different cell types within a tissue core), intra-tumour heterogeneity (ITH), and inter-observer variability 
(two pathologists) rather than to the malperformance of the DISH assay. Moreover, manual evaluation of DISH is 
labour intensive and becomes infeasible for large-scale cohorts. These problems emphasized the need for accurate 
detection of molecular signals, fast CNV assessment, and quantitative measurement of tumour heterogeneity.
An image-based computational workflow - ISHProfiler. To automate DISH analysis and produce 
unbiased assessment of CNVs, we developed an image-based computational workflow (Fig. 1f) for ISH assays 
(ISHProfiler), which has been integrated into the open source software TMARKER16. ISHProfiler uses supervised 
machine learning and statistical methods to generate computational models of CNV based on the classification 
of detected molecular signals, without relying on computationally intensive algorithms for single-cell recogni-
tion13,14. The workflow consists of three major algorithmic steps: First, each tissue was digitized, pre-processed, 
and resized. Second, DISH signals (1,000 to 5,000 signals per tissue core, and more than a million for a whole 
slide image) were detected by the circular Hough transform17. Third, a support vector machine (SVM) model18 
was trained and 5-fold cross validated on the basis of an independent training set of PTEN DISH signals with 
expert annotations (Supplementary Fig. S6). The final model was used to classify the signals into five classes: 
PTEN, CEP10, mixed class PTEN+ CEP10, background noise and cell stains; about 30% of signals were classified 
as PTEN or CEP10. Analogous to the novel ratio scoring method, the global ratio was defined as the division of 
all PTEN by all CEP10 signals in a single tissue core.
Using all 71 global ratios as prediction scores, receiver operating characteristic (ROC) analysis yielded a large 
area under the curve value of 0.99 (95% CI [0.96–1.00]), and found the optimal dichotomization threshold at 
84% with a total accuracy of 97.2% (Supplementary Fig. S7 and Supplementary Table S3), enabling objective 
determination of the threshold that was previously determined in an empirical manner9. Moreover, the three-step 
algorithm is an independent process, thus loop iterations over each tissue or sub-image of a large whole slide can 
be executed in parallel. Thus, ISHProfiler achieved a classification accuracy similar to that of manual assessment, 
while the evaluation time was tremendously reduced, outperforming manual assessment by at least four orders 
of magnitude.
ISHProfiler for visualization and quantification of multi-level heterogeneity. Deletion of PTEN 
has been shown to be heterogeneous and subclonal19, and is associated with tumour progression9,20–22. Therefore, 
analysis of PTEN status provides an appropriate means for investigating tumour heterogeneity and subclonal 
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evolution. Dichotomization of PTEN status into deletion and non-deletion using an empirical9 or single-valued 
threshold is arbitrary, particularly in the presence of tumour heterogeneity. We applied ISHProfiler to the 71 
tissue cores and generated respective signal colour maps, in which PTEN and CEP10 were illustrated as coloured 
squares (Fig. 1g). The descriptive colour pattern allowed for a straightforward visual categorization of these tis-
sues into two major classes of homogenous and heterogeneous events, three subclasses and six prototypes (Fig. 2). 
While the three subclasses further divided the homogenous events into deletion and non-deletion, the six proto-
types differentiated subtypes such as homozygous deletion, hemizygous deletion, cellular homogeneity, cellular 
heterogeneity with either homogeneous or heterogeneous genetic status, and ITH.
To quantify cellular, inter-, and intra-tumour heterogeneity among and within individual tissue cores, we 
extended ISHProfiler by incorporating the randomized local ratio (RLR) and the randomized local density (RLD) 
into the analysis. While the global ratio characterized each tissue core as a single number, the RLR and RLD 
measured the distribution of local ratios and signal densities that were computed in the respective vicinity of cells 
at random (Supplementary Fig. S8), providing a plausible quantification of heterogeneity at multiple levels. We 
then constructed multivariate features by extracting statistics, such as central tendency and dispersion from the 
distributions of all RLR and RLD, to which we performed principal component analysis (PCA) for dimensionality 
reduction.
Figure 1. FISH, DISH and ISHProfiler for quantification and visualization of genetic alterations. (a) PTEN 
loss assessed by FISH on FFPE tissue sections as an independent negative prognostic marker for PC. Cumulative 
bar charts showing the association of PTEN deletion based on the percentage of aberrant nuclei with different 
prostate tissue types. P value was calculated with the two-side Fisher’s exact test. (b) Cumulative bar charts for 
the ratio. (c) Scatterplot of the percentage aberrant nuclei against the ratio, colour-coded by tissue types. The 
threshold was set to 60% for both scoring methods. Linear correlation revealed r = − 0.9492 and P < 0.001.  
(d) Example of a PC lymph node metastasis showing cellular heterogeneity for PTEN status. (e) Zoomed image 
showing PC with PTEN deletion (right side) and lymph node structures without PTEN deletion (left side). Black 
signal: PTEN gene; red signal: CEP10. Scale bar, 10 μm. (f) Computational workflow ISHProfiler. Circled letters 
correspond to the respective results shown in (d,g). (g) Detected and classified PTEN gene and CEP points are 
displayed as a signal colour map. Black signal: PTEN gene; red signal: CEP10; green signal: PTEN+ CEP10.
www.nature.com/scientificreports/
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We further applied a probabilistic model by Gaussian mixture modelling (GMM) to assign the 71 tissue cores 
into three clusters approximating the three subclasses defined in (Fig. 2), and calculated the Mahalanobis dis-
tances of each point to the centroid (the mean of a designated distribution) of the homogeneous deletion class. 
The Mahalanobis distance measures the distance (the amount of standard deviations) between a given tissue core 
and the centroid. In the two-dimensional PCA subspace, tissues with both cellular and intra-tumour heteroge-
neity lay farthest from the centroids of the two homogeneous classes (C1 and C2 in Fig. 3a), followed by tissues 
with ITH, while tissues with homozygous and hemizygous deletion, and non-deletion were placed in an identical 
order as in (Fig. 2). Thus, the top-left to bottom-right diagonals can be interpreted as the progression of PTEN 
deletion and the anti-diagonal as the degree of heterogeneity for PTEN status. In addition, inter-tumour hetero-
geneity was exemplified by the pairwise distance of each tissue core, and cellular heterogeneity by the discrepant 
position of the two lymph node metastases (top centre and far right spot; Fig. 3a) that exhibited different amounts 
of lymphoid tissue.
To examine the robustness of the two random methods, we varied the number of random points for each 
core from 201 to 300, recalculated RLR and RLD, performed PCA, and applied GMM. Each core was then rep-
resented by an ellipse (Fig. 3a) with its centre as the mean of the 100 experiments and the axes as the 95% CI. 
This perturbation experiment suggested that ISHProfiler is not only robust but also insensitive to a designated 
range of randomness. We predefined the number of classes to fit a GMM to our data. To determine an optimal 
number of classes automatically, we used Akaike’s Information Criterion (AIC) fit statistic to choose the best fit-
ting GMM over varying numbers of components from one to five. We found that the AIC was minimized for the 
three-component GMM, in accordance with our manual categorization.
Application to whole-slide images and histomorphological-genetic integration. To further 
investigate the robustness and versatility of ISHProfiler, we applied our workflow to an additional dataset, in 
which a whole tissue slide (108,000 × 138,000 pixels) of a transurethrally resected CRPC was hybridized with 
PTEN DISH and digitized with a Hamamatsu scanner. Using the same computational parameters and SVM clas-
sification model, our workflow classified more than one million PTEN and CEP10 signals (Fig. 3b–d), attaining 
considerable agreement with a serial section that was immunohistochemically stained with anti-PTEN antibody 
(Supplementary Fig. S9). The high-throughput application of ISHProfiler analysis to the whole slide allowed for 
the generation of a three-dimensional graph with each bar representing the ratio of PTEN to CEP10 for each 
individual local tumour foci (Supplementary Fig. S10). The bar graph reveals the complex intra-tumour CNV 
landscape of the PTEN locus and highlights focal PTEN ITH.
Intra-ductal carcinoma of the prostate (IDC-P) represents an aggressive disease. PTEN loss has been reported 
as a potentially useful marker to distinguish IDC-P from high-grade prostatic intraepithelial neoplasia (PIN) by 
immunostaining in biopsy specimens with significant clinical implications23. On the basis of this observation, 
we stained a large tissue section of an IDC-P with PTEN DISH and visualized CNV using the signal colour map. 
Figure 2. Visualization of multi-level heterogeneity by ISHProfiler. Heterogeneity of PTEN CNV of a 
given tissue core can be visually classified into two major groups (homogeneous and heterogeneous classes), 
three subclasses (C1 and C2: homogeneous deletion and non-deletion, and C3: heterogeneous class) or six 
subgroups (homozygous deletion, hemizygous deletion, cellular homogeneity, cellular heterogeneity with either 
homogeneous or heterogeneous genetic status, and ITH), which are illustrated as original tissue core image, 
signal colour map, and sketch.
www.nature.com/scientificreports/
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The obtained heterogeneous topological pattern of molecular signals depicted PTEN homozygous deletion in the 
IDC-P component, in contrast to the retained PTEN status in the surrounding benign basal cells. This pattern 
was recapitulated in intra-ductal areas on serial sections stained with immunohistochemistry (IHC) (Fig. 4). 
This integrative analysis of genetic profiling with tissue morphology suggested that visualization by ISHPropfiler 
provides high-resolution single locus copy-number information in histomorphologically intact tissues, enabling 
the evaluation of ITH at single-cell level without compromising the ability to determine morphological and top-
ological relationships of lesions.
Generalizability tested for other genes and cancers. Finally, we explored the general applicability of 
our ISHProfiler workflow by applying it to additional cancer entities and genetic loci. For measuring amplifica-
tion of 19q12 including CCNE1 and URI in ovarian24 and endometrial cancers, we used ISHProfiler to generate 
signal colour maps of two selected tissue cores (Supplementary Fig. S11). The global ratio of 19q12 to CEP19 and 
RLR at a threshold of 2.0 for both cancers closely matched manual assessment24. Moreover, we applied ISHProfiler 
to a whole slide of ovarian cancer and generated a signal colour map and a bar graph (Supplementary Fig. S12). 
Both figures showed no ITH as validated by manual inspection, demonstrating ISHProfiler’s capability to dis-
criminate between ITH and homogenous events, even for different genes and cancer tissues. Furthermore, our 
ISHProfiler workflow successfully detected a heterogeneous HER2 gene amplification in a well-differentiated 
gastric adenocarcinoma, hybridized with HER2 and CEP17 molecular probes. The amplified regions agreed with 
the overexpression of HER2 detected by immunohistochemical staining (Fig. 5).
Discussion
Genetic ITH has critical impact on cancer diagnosis and treatment, and is associated with cancer evolution. 
Methods such as genome sequencing only provide single-cell information without spatial context, whereas 
stand-alone FISH and IHC can only evaluate ITH in a qualitative and subjective fashion. These obstacles have 
prevented ITH to be properly evaluated in research and clinical practice, leading to poor understanding of cancer 
evolution at single cell level. Our image-based computational workflow: ISHProfiler (Fig. 6 and Supplementary 
Methods) enabled for the first time the unbiased and reproducible quantification of genetic ITH on human cancer 
tissues with visualization tools, while simultaneously preserving the spatial and morphological information at 
Figure 3. Quantification of tumour heterogeneity by ISHProfiler. (a) Tissue core distribution in the two-
dimensional principal component analysis subspace (n = 71), superimposed with selected signal colour maps 
shown in Fig. 2. Ellipses refer to individual tissue cores. The axes of the ellipses indicate the 95% CI of an 
experiment with a total of n = 100 repetitions by varying the number of random points from 201 to 300. The 
number is the Mahalanobis distance of each point to the respective centroids that are illustrated as stars. (b) A 
signal colour map generated from a whole slide image of CRPC shows detected and classified PTEN and CEP10 
signals. (c,d) Zoomed image of areas marked with arrows in (b). Scale bar, 10 μm.
www.nature.com/scientificreports/
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single cell level. Therefore, clinical integration of our computational ISHProfiler bridges the gap between tradi-
tional molecular pathology and genomic studies.
Figure 4. Analysis of IDC-P. (a) Whole slide image of IDC-P stained with PTEN DISH and visualized by a 
signal colour map as in Fig. 1g. (b,c) Zoomed versions of A, showing PTEN deletion in intra-ductal tumour cells 
in (b) and a signal colour map in (c). Red scale bar, 10 μm and black scale bar, 100 μm. (d–g) Serial sections of 
the same tissue block. Scale bar 100 μm. PTEN IHC (d), hematoxylin-eosin (H&E) (e), PIN4 IHC (f), and ERG 
IHC (g).
www.nature.com/scientificreports/
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The distribution of individual tissue spots with different degrees of CNV heterogeneity in the scatterplot 
(Fig. 3a) indicated that current grouping of tumor malignancy into discrete categories was subjective and arbi-
trary. Our integrative system with both cellular spatial organization and genetic ITH provides totally different 
information that is complementary to each other, essentially facilitating the investigation of patient outcome and 
the inference of tumor evolution.
Computation in ISHProfiler is high-throughput, because it neither relies on morphological features of cells, 
nor their detection, completely omitting computationally expensive algorithms such as segmentation, fea-
ture extraction and complex predictive modelling that are regarded as essential algorithmic steps for various 
image-based biological and translational studies11,13,14,16,25–30.
Manual analysis of genetic alterations based on molecular ISH signals relies solely on the expertise of trained 
pathologists. Visual inspection of histological slides and manual scoring of CNV are prone to inconsistent assess-
ment among different pathologists, with different laboratory settings, and over extended project durations10–12. 
Besides, any tissue sample is a two-dimensional section from a three-dimensional specimen, thus the amount of 
genes and corresponding CEPs in each single cell may not reflect its bona-fide quantity. Notably, statistical aver-
aging over multiple single-cell based ratio counting9,12,24,31 propagates the error at the single-cell level to a given 
tumour area, leading to inaccurate measurement of underlying genetic variations. Cellular and intra-tumour 
heterogeneity, intrinsic staining artefacts, and batch effects further complicate the assessment, especially when 
single-valued thresholds are used for dichotomizing genetic status. ISHProfiler alleviates these problems by using 
the region-based global ratio in conjunction with automatic thresholding by ROC analysis. Possible false pos-
itively or negatively detected or classified signals by ISHProfiler at single-cell resolution are irrelevant for the 
final dichotomization of genetic alteration (deletion, normal, or amplification) at the tissue core or whole slide 
Figure 5. Analysis of HER2 in a whole slide tissue of gastric caner. (a) A selected area of a whole tissue slide 
of gastric cancer. Scale bar 100 μm. (b) A signal colour map with HER2, CEP17 and HER2+ CEP17 illustrated 
by black, red, and green signals respectively. (c) A serial section immunohistochemically stained by anti-HER2 
antibody. Scale bar 100 μm. (d) A zoomed image of (a). Scale bar 10 μm. (e) A zoomed version of (b).
www.nature.com/scientificreports/
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resolution, because systematic and random errors are likely cancelled out when thousand and millions of molec-
ular signals are involved in the calculation, while inconsistencies and biases associated with manual assessment 
is more error-prone10–12. Additionally, RLR and RLD take advantage of local distribution in random neighbour-
hoods, which allows us to quantify tumour heterogeneity as distribution.
Our ISHProfiler was able to detect allelic gains and loss in different tumor tissues, independent of genes of 
interest and associated CEPs, without any parameter adjustment for point detection and classification, if sim-
ilar DISH staining protocols and digitization procedures were used. However, some of the limitations are the 
need for parameter tuning of the circular Hough transform and the construction of a new training image set for 
re-validating the classification model, if the DISH staining or image acquisition is performed in another labo-
ratory under different conditions. However, this recalibration problem can be solved by implementing highly 
sensitive point detection algorithms, building a graphic user interface for efficient expert annotation of multiple 
genes, and providing a set of classification models for distinct DISH assays, staining protocols, and digitization 
procedures.
Genomics and proteomics studies rely on the selection of patient tissues by trained pathologists32–34. Such 
selection has traditionally been accomplished by staining whole slide tissues with H&E, IHC or ISH, followed by 
manual evaluation of small selected regions of interest. Our quantitative signal colour map, which preserves tissue 
topology and combines genetic analysis with clinico-pathological assessment, will provide accurate and objective 
punch guidance for the optimal hotspot selection of heterogeneous tumour tissues.
Our generic ISHProfiler can be potentially used for reliable quantification of heterogeneous allelic gains and 
losses of any gene in any tissue specimen hybridized at single-cell level, thereby enabling precise patient stratifi-
cation and permitting broad applications in tissue-based biomedical research.
Methods
Study design and reporting. We have used a PTEN FISH PC cohort, a PTEN DISH PC dataset, several 
DISH whole slide images of PTEN, 19q12, and HER2, and two tissue cores stained with DISH probes for 19q12. 
In our retrospective PC cohort, PTEN deletion expression could be observed in 78 of 339 (23%) RPE specimens. 
We further estimated that the occurrence of PTEN deletion expression would double the risk of death during fol-
low up, resulting in a hazard ratio of 2.0. The estimation of statistical power versus total sample size N for different 
hazard ratios was shown in (Supplementary Fig. S13). Accordingly, the available sample size of 339 analysable 
patients would be sufficient to detect a difference concerning death recurrence with a significance of P < 0.05 
and a power of almost 100%. For transparent and complete reporting of the prognostic role of PTEN FISH we 
followed the REporting recommendations for tumour MARKer prognostic studies (REMARK)32.
Cancer patient samples. A total of 424 FFPE tissue samples were retrieved from the archives of the Institute 
of Surgical Pathology, University Hospital Zurich, Switzerland32,35–38. H&E-stained slides of all specimens were 
evaluated by two experienced pathologists to identify representative areas for tissue microarray (TMA) construc-
tion. One tissue core (diameter 0.6 mm and thickness of 4 μm) of a representative tumour area per patient was 
taken from a “donor” block and arranged in a new “recipient” block using a customized instrument. Tumour stage 
Figure 6. Workflow and applications of ISHProfiler. (a) A synopsis of the manual analysis of FISH and DISH, 
and the computational workflow ISHProfiler. (b) Applications of ISHProfiler.
www.nature.com/scientificreports/
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and Gleason score of the cohort were assigned according to the International Union Against Cancer (UICC) and 
WHO/ISUP criteria. The study was approved by the Cantonal Ethics Committee of Zurich (StV-No. 2008-0025) 
and the associated methods were carried out in accordance with the approved guidelines. Effectively, 424 samples 
were used in the FISH analysis and a subset of 71 samples was used for DISH manual assessment and computa-
tional analysis.
Detection of the 19q12 amplicon using the recently established DISH assay was performed as previously 
described for the ovarian and endometrial cancers24,39. The amplification status of the 19q12 region was identified 
using a DNA probe set (Ventana) by measuring the copy number ratio of the 19q12 amplicon (black signals) to 
the CEP19 (red signals). The 19q12 DISH probe is a DNA probe that covers approximately 560 kb containing the 
coding sequences of CCNE1 and URI. Silver-enhanced, bright-field HER2 (black signals) and CEP17 (red signals) 
DISH staining in the gastric cancer40 was performed using the respective kits (Ventana) according to published 
procedures31,40. Analysis of ovarian, endometrial, and gastric cancer patients was approved by the Cantonal Ethics 
Committee of Zurich (KEK-ZH-No. 2014-0604) and the associated methods were carried out in accordance with 
the approved guidelines.
PTEN FISH analysis. For PTEN deletion analysis, a dual-colour FISH was performed using commercially 
available DNA probes for the region 10q23.3 (Spectrum Orange, PTEN locus-specific probe; Abbott Molecular) 
and 10p11.1-q11.1 (Spectrum Green, centromeric probe (CEP) of chromosome 10; LSI PTEN/CEP10; Abbott 
Molecular), as described previously12. Each tissue core was evaluated for each FISH probe by manually counting 
signals in 20–60 intact non-overlapping interphase nuclei, using a fluorescence microscope (Leica DM6000 B). 
In case of insufficient staining (n = 5), additional sections of the FFPE tissue blocks were hybridized with PTEN 
FISH. Manual scoring was performed in tumour areas with loss of PTEN signals. The average of two experienced 
pathologists manual, independent assessment led to the final score. Two scoring methods were used: the percent-
age of aberrant nuclei and the ratio of PTEN to CEP10 signals. As threshold for PTEN deletion, the percentage 
of aberrant nuclei was used in accordance to previous publications9: hemizygous PTEN deletion was defined as 
the presence of fewer PTEN signals than CEP10 signals in at least 60% of counted nuclei. Homozygous PTEN 
deletion was defined if at least one third (33%) of aberrant nuclei revealed zero PTEN signal in a tissue core, with 
the presence of one or two PTEN signals in adjacent normal cells. Accordingly, PTEN deletion was defined if the 
average ratio of PTEN to CEP10 signals was less than or equal to 60%.
PTEN DISH analysis. A BenchMark ULTRA automated stainer was used for the optimization and perfor-
mance evaluation of the DISH assay for CEP10 and PTEN DNA targets. In this assay, a black signal represents the 
PTEN probe a red signal corresponds to the CEP10, which were visualized with ultraView SISH DNP and Red 
ISH DIG detection kit respectively, after hybridization with the PTEN DNP probe and CEP10 probe cocktail. All 
tissue sections were counterstained with hematoxylin II and bluing reagent (Ventana). The threshold of 60% for 
the ratio was used.
ALU II silver in situ hybridization (SISH). Another gene probe, ALU II, an important group of widely 
distributed sequence repeats in the human genome, was used as a positive control for viable DNA on the same 
tissue specimens and detected by a single colour SISH assay. For ALU II SISH, the ALU gene target was visualized 
with ultraView SISH DNP detection kit after hybridization with the ALU II DNP Probe (Ventana). A total of 13 
cores were excluded from further analyses because of unviable DNA (Supplementary Fig. S4), lack of target tissue, 
or weak CEPs.
ERG break-apart FISH and SPOP mutation. We used a FISH assay to detect ERG rearrangement at the 
chromosomal level on FFPE specimens. Hence, we performed a split-signal-approach, with two probes spanning 
the ERG locus as described earlier41. Two experienced pathologists independently assessed all cases and at least 
100 nuclei per case were evaluated. The assay is also capable of differentiating between two different mechanisms 
of ERG rearrangement. Methods and results of SPOP mutation analysis have already been published in part 
previously36.
Immunohistochemistry (IHC). IHC was performed using a Ventana Benchmark automated staining 
system with two-micrometer TMA tissue sections. Two pathologists performed a blinded evaluation of the 
immunostained slides without knowledge of clinical data. Cytoplasmic PTEN and nuclear immunoreactivity 
of ERG was estimated using a semi-quantitative four-step scoring system (0–3): 0, negative; 1, weak positive; 2, 
strong positive; 3, very strong positive. For negative controls, the primary antibody was omitted. The specificity 
of the ERG antibody has been thoroughly validated in former studies42. The following antibodies were used for 
IHC: anti-ERG (Ventana; EPR3864), anti-PTEN (Dako; clone 6H2.1), anti-HER2 (Ventana; PATHWAY HER2, 
clone 4B5). In addition, an antibody cocktail comprising p63, CK5, CK14, and P504S (Biocare Medical; PIN-4 
Cocktail) was used.
Statistical analysis. Statistical association between clinic-pathological and molecular parameters was tested 
by two-sided Fisher’s exact test or Pearson’s chi-squared test. Nonparametric Kaplan-Meier estimators were used 
to analyze overall, disease-specific and recurrence-free survival. Patients were censored at the time of their last 
clinical follow-up visit. Simultaneous 95% confidence bands were computed for the whole range of time values. 
Differences between survival estimates were evaluated by the log-rank test. The threshold for statistical signifi-
cance was set to P < 0.05. Univariate and multivariable Cox regression models were estimated. Multivariate step-
wise reverse selection was set to P = 0.1 as the limit. In the forest plot (Supplementary Fig. S3), the dashed line 
was drawn at the no effect point (hazard ratio of 1.0). Horizontal lines represent a 95% CI. The mid-point of the 
box denotes the mean effect estimate and the area of the box represents the weight for each subgroup. Statistical 
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analyses were performed using PASS (2008), survival, OIsurv, and metaphor packages in R (version 3.2.0), and 
SPSS (version 22.0).
In the ROC analysis, we used global ratios as the classifier prediction scores and DISH manual assessment as 
true class labels. Point wise confidence bands for the area under the curve were computed by generating 1,000 
bootstrap replicates. The optimal operating point by the false positive rate and true positive rate was obtained 
by finding the slope that satisfies the optimality criterion. The optimal operating point determined the optimal 
threshold, which was then used to dichotomize the global ratios for determining genetic status.
We assume the random variables (RLR and RLD) are independent and identically distributed and the con-
structed features for the GMM are normally distributed.
Image digitization. The bright-field and fluorescence slide scanner Axio Scan.Z1 (Carl Zeiss) was used to 
digitize tissue cores with a resolution of x40 (0.11 μm/pixel) according to manufacturer’s instructions. To show 
the general applicability of our ISHProfiler, we also used a C9600 NanoZoomer 2.0-HT Digital slide scanner 
from (Hamamatsu) with a resolution of 40x (0.23 μm/pixel). The Zeiss scanner was used for digitizing all prostate 
cancer tissue cores and an ovarian cancer tissue core, and the Hamamatsu scanner for digitizing an endometrial 
cancer tissue core, and whole slides of prostate, ovarian and gastric cancers.
Image-based computational workflow (ISHProfiler). Tissue cores or slides were digitized and 
pre-processed (white balancing, deconvolution, and contrast modification) using the scanner’s default 
auto-correction settings. Images were then resized by bicubic interpolation to 4096 × 4096 pixels for efficient 
tiling (4096 = 212) and served as input data for the computational workflow ISHProfiler. Pseudocode of the 
ISHProfiler, details about the parameter tuning, and applications of ISHProfiler to other genes are provided in the 
Supplementary Information.
The RLR and RLD were calculated as follows. First, a predefined number of random points were generated, 
such that these points were uniformly distributed over an entire tissue core, yet as few gene and CEP signals as 
possible were sampled without replacement (default set to 300, Supplementary Fig. S8). The coordinate of each 
random point was then substituted by the coordinate of its closest CEP point. Second, in the neighborhood of 
such a CEP point, all gene and CEP points that lay within a predefined radius (default set to 60 pixels, such that at 
least one adjacent cell was included in the neighborhood) were recorded. Third, for each neighborhood, the ratio 
was the division of all genes by all CEP signals and the density was the total number of gene and CEP signals. The 
ratio and density distributions over the neighborhoods were defined as the RLR and RLD respectively.
For each tissue core, we extracted mean, median and standard error of the mean from the distributions of the 
RLR and RLD (3 × 2 = 6 dimensions), to which we performed principal component analysis (PCA) for reduc-
ing the dimensionality from six to two. In the two dimensional PCA subspace, we then applied a probabilistic 
model by Gaussian mixture modeling (GMM) to cluster the 71 cores into three classes. By incorporating the 
domain knowledge that homogeneous deletion exhibits a lower gene to CEP ratio than cases with homogeneous 
non-deletion and multi-level heterogeneity, we could locate the centroid of this homogeneous deletion class (cen-
troid C1 in Fig. 3A) and calculated the Mahalanobis distances of each point to it.
The computational workflow was implemented in MATLAB (R2014b) and tested on a MacPro (2014). 
MATLAB built-in functions for the circular Hough transform (imfindcircles) and ROC analysis (perfcurve) were 
used. The software package LIBSVM43 (version 3.18) was used to train, validate and test SVM models on the data.
Data and materials availability. The source code for the method presented in this manuscript is provided 
in the Supplementary Software and on www.wildlab.ch/ish. The dataset of 71 tissue core images is available in 
the online repository Harvard Dataverse: https://dataverse.harvard.edu/dataset.xhtml?persistentId= doi:10.7910/
DVN/RRKMHC. In addition, the MATLAB code with basic ISHProfiler functionalities has been deployed as a 
Java plugin for the free open source software TMARKER (http://www.nexus.ethz.ch/equipment_tools/software/
tmarker.html).
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